{"success":true,"data":{"pressRelease":{"id":"50108","rtpr_id":"nGNX8NBN4W","ticker":"BCTXL","exchange":"NASDAQ","all_tickers":["BCTXL","BCTXZ","BCT"],"title":"BriaCell Therapeutics Announces Pricing of Offering","author":"Globe Newswire","published_at":"2026-05-31T23:59:35.099Z","article_body":"PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) --\nBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT)\n(“BriaCell” or the “Company”), a clinical-stage biotechnology company\ndeveloping novel immunotherapies to transform cancer care, today announced the\npricing of a best-efforts offering of 1,449,300 common shares. Each common\nshare is being sold at an offering price of $3.25 per share. All of the common\nshares in the offering are being offered by the Company. Total gross proceeds\nfrom the offering, before deducting placement agent’s fees and other\noffering expenses, are expected to be approximately $4.7 million. The offering\nis expected to close on June 2, 2026, subject to satisfaction of customary\nclosing conditions. The Company is relying upon the exemption set forth in\nSection 602.1 of the TSX Company Manual, which provides that the TSX will not\napply its standards to certain transactions involving eligible interlisted\nissuers on a recognized exchange, such as Nasdaq.\n\nThe Company intends to use the net proceeds from the offering for working\ncapital requirements, general corporate purposes, and the advancement of\nbusiness objectives.\n\nThinkEquity is acting as sole placement agent for the offering.\n\nThe securities described above are being offered and sold by the Company\npursuant to a shelf registration statement on Form S-3 (File No. 333-276650),\nincluding a base prospectus, filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on January 22, 2024 and declared effective on\nJanuary 31, 2024. The offering is being made only by means of a written\nprospectus. A final prospectus supplement and accompanying prospectus relating\nto the offering will be filed with the SEC and can be accessed for free on the\nSEC’s website at www.sec.gov. Copies of the final prospectus supplement and\nthe accompanying prospectus relating to the offering may be obtained, when\navailable, from the offices of ThinkEquity, 17 State Street, 41(st) Floor, New\nYork, New York 10004.\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy, nor shall there be any sale of these securities in any state\nor jurisdiction in which such an offer, solicitation or sale would be unlawful\nprior to registration or qualification under the securities laws of any such\nstate or jurisdiction.\n\nAbout BriaCell Therapeutics Corp.\n\nBriaCell is an immuno-oncology-focused biotechnology company developing\ntargeted and effective approaches for the management of cancer. More\ninformation is available at https://briacell.com/.\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” that are subject\nto substantial risks and uncertainties. All statements, other than statements\nof historical fact, contained in this press release are forward-looking\nstatements. Forward-looking statements contained in this press release may be\nidentified by the use of words such as “anticipate,” “believe,”\n“contemplate,” “could,” “estimate,” “expect,” “intend,”\n“seek,” “may,” “might,” “plan,” “potential,”\n“predict,” “project,” “target,” “aim,” “should,”\n“will,” “would,” or the negative of these words or other similar\nexpressions, although not all forward-looking statements contain these words.\nForward-looking statements are based on BriaCell’s current expectations and\nare subject to inherent uncertainties, risks, and assumptions that are\ndifficult to predict. Further, certain forward-looking statements are based on\nassumptions as to future events that may not prove to be accurate. These and\nother risks and uncertainties are described more fully under the heading \"Risk\nFactors\" in the Company's most recent Annual Report on Form 10-K, and under\n“Risks and Uncertainties” in the Company's other filings with the Canadian\nsecurities regulatory authorities and the U.S. Securities and Exchange\nCommission, all of which are available under the Company's profiles on SEDAR+\nat www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements\ncontained in this announcement are made as of this date, and BriaCell\nTherapeutics Corp. undertakes no duty to update such information except as\nrequired under applicable law.\n\nNeither the Toronto Stock Exchange nor its Regulation Services Provider (as\nthat term is defined in the policies of the Toronto Stock Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nContact Information\n\nCompany Contact:\nWilliam V. Williams, MD\nPresident & CEO\n1-888-485-6340\ninfo@briacell.com \n\nInvestor Relations Contact:\ninvestors@briacell.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/88b9408d-31d4-4afd-beff-f855719a15d8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8NBN4W","title":"BriaCell Therapeutics Announces Pricing of Offering","author":"Globe Newswire","ticker":"BCTXL","created":"2026-05-31T23:59:35.099Z","tickers":["BCTXL","BCTXZ","BCT"],"exchange":"NASDAQ","article_body":"PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) --\nBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT)\n(“BriaCell” or the “Company”), a clinical-stage biotechnology company\ndeveloping novel immunotherapies to transform cancer care, today announced the\npricing of a best-efforts offering of 1,449,300 common shares. Each common\nshare is being sold at an offering price of $3.25 per share. All of the common\nshares in the offering are being offered by the Company. Total gross proceeds\nfrom the offering, before deducting placement agent’s fees and other\noffering expenses, are expected to be approximately $4.7 million. The offering\nis expected to close on June 2, 2026, subject to satisfaction of customary\nclosing conditions. The Company is relying upon the exemption set forth in\nSection 602.1 of the TSX Company Manual, which provides that the TSX will not\napply its standards to certain transactions involving eligible interlisted\nissuers on a recognized exchange, such as Nasdaq.\n\nThe Company intends to use the net proceeds from the offering for working\ncapital requirements, general corporate purposes, and the advancement of\nbusiness objectives.\n\nThinkEquity is acting as sole placement agent for the offering.\n\nThe securities described above are being offered and sold by the Company\npursuant to a shelf registration statement on Form S-3 (File No. 333-276650),\nincluding a base prospectus, filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on January 22, 2024 and declared effective on\nJanuary 31, 2024. The offering is being made only by means of a written\nprospectus. A final prospectus supplement and accompanying prospectus relating\nto the offering will be filed with the SEC and can be accessed for free on the\nSEC’s website at www.sec.gov. Copies of the final prospectus supplement and\nthe accompanying prospectus relating to the offering may be obtained, when\navailable, from the offices of ThinkEquity, 17 State Street, 41(st) Floor, New\nYork, New York 10004.\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy, nor shall there be any sale of these securities in any state\nor jurisdiction in which such an offer, solicitation or sale would be unlawful\nprior to registration or qualification under the securities laws of any such\nstate or jurisdiction.\n\nAbout BriaCell Therapeutics Corp.\n\nBriaCell is an immuno-oncology-focused biotechnology company developing\ntargeted and effective approaches for the management of cancer. More\ninformation is available at https://briacell.com/.\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” that are subject\nto substantial risks and uncertainties. All statements, other than statements\nof historical fact, contained in this press release are forward-looking\nstatements. Forward-looking statements contained in this press release may be\nidentified by the use of words such as “anticipate,” “believe,”\n“contemplate,” “could,” “estimate,” “expect,” “intend,”\n“seek,” “may,” “might,” “plan,” “potential,”\n“predict,” “project,” “target,” “aim,” “should,”\n“will,” “would,” or the negative of these words or other similar\nexpressions, although not all forward-looking statements contain these words.\nForward-looking statements are based on BriaCell’s current expectations and\nare subject to inherent uncertainties, risks, and assumptions that are\ndifficult to predict. Further, certain forward-looking statements are based on\nassumptions as to future events that may not prove to be accurate. These and\nother risks and uncertainties are described more fully under the heading \"Risk\nFactors\" in the Company's most recent Annual Report on Form 10-K, and under\n“Risks and Uncertainties” in the Company's other filings with the Canadian\nsecurities regulatory authorities and the U.S. Securities and Exchange\nCommission, all of which are available under the Company's profiles on SEDAR+\nat www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements\ncontained in this announcement are made as of this date, and BriaCell\nTherapeutics Corp. undertakes no duty to update such information except as\nrequired under applicable law.\n\nNeither the Toronto Stock Exchange nor its Regulation Services Provider (as\nthat term is defined in the policies of the Toronto Stock Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nContact Information\n\nCompany Contact:\nWilliam V. Williams, MD\nPresident & CEO\n1-888-485-6340\ninfo@briacell.com \n\nInvestor Relations Contact:\ninvestors@briacell.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/88b9408d-31d4-4afd-beff-f855719a15d8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-31T23:59:35.147294668Z","server_sent_at_ms":1780271975147},"received_at":"2026-05-31T23:59:35.205Z","source_url":null},"analysis":{"id":"39540","press_release_id":"50108","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["best-efforts offering structure suggests uncertainty in full subscription","use of proceeds for 'working capital' may indicate liquidity pressure"],"eventType":"offering","narrative":"BriaCell Therapeutics priced a best-efforts offering of 1,449,300 common shares at $3.25 per share.\n\nThe deal generates approximately $4.7 million in gross proceeds, with ThinkEquity acting as sole placement agent.\n\nThe company intends to use net proceeds for working capital and general corporate purposes, closing on June 2, 2026.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"BriaCell raises $4.7M in best-efforts offering at $3.25/share; watch for dilution impact and liquidity signals."},"keyFigures":{"dealValueUsd":4700000,"offeringPrice":3.25,"sharesOffered":1449300,"customDimensions":{"gross_proceeds":"$4.7 million"}},"quotedText":"The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.","namedEntities":{"people":[{"name":"William V. Williams, MD","role":"President & CEO"}],"products":[],"companies":[{"name":"BriaCell Therapeutics Corp.","ticker":"BCTX","relationship":"filer"},{"name":"ThinkEquity","relationship":"placement agent"}],"dollarAmounts":[{"amount":"$3.25","context":"offering price per share"},{"amount":"$4.7 million","context":"total gross proceeds"}]},"materialImpact":{"score":3,"reasoning":"The company is raising ~$4.7M via a best-efforts offering of common shares. While the absolute dollar amount is modest, the 'best-efforts' structure and use of proceeds for 'working capital' signals potential liquidity constraints for a clinical-stage biotech. Dilution is immediate."},"tickerRelevance":{"others":[{"ticker":"BCTX","relevance":"primary listing (Nasdaq)"},{"ticker":"BCTXZ","relevance":"warrant series"},{"ticker":"BCT","relevance":"TSX listing"}],"primary":"BCTXL"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small_cap_offering","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"BriaCell Therapeutics priced a best-efforts offering of 1,449,300 common shares at $3.25 per share.\n\nThe deal generates approximately $4.7 million in gross proceeds, with ThinkEquity acting as sole placement agent.\n\nThe company intends to use net proceeds for working capital and general corporate purposes, closing on June 2, 2026.","key_figures":{"dealValueUsd":4700000,"offeringPrice":3.25,"sharesOffered":1449300,"customDimensions":{"gross_proceeds":"$4.7 million"}},"named_entities":{"people":[{"name":"William V. Williams, MD","role":"President & CEO"}],"products":[],"companies":[{"name":"BriaCell Therapeutics Corp.","ticker":"BCTX","relationship":"filer"},{"name":"ThinkEquity","relationship":"placement agent"}],"dollarAmounts":[{"amount":"$3.25","context":"offering price per share"},{"amount":"$4.7 million","context":"total gross proceeds"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-31T23:59:46.087Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small_cap_offering","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":10860,"modelName":"george-droid-qwen-72b"}}